Explore

Trendline Trendline
FDA Grants Star Therapeutics Rare Pediatric and Breakthrough Therapy Designations for Von Willebrand Disease Treatment

FDA Grants Star Therapeutics Rare Pediatric and Breakthrough Therapy Designations for Von Willebrand Disease Treatment

FDA Grants Star Therapeutics Rare Pediatric and Breakthrough Therapy Designations for Von Willebrand Disease Treatment
Trendline Trendline
Star Therapeutics Gains FDA Designations for VGA039 in Von Willebrand Disease Treatment

Star Therapeutics Gains FDA Designations for VGA039 in Von Willebrand Disease Treatment

Star Therapeutics Gains FDA Designations for VGA039 in Von Willebrand Disease Treatment
Trendline Trendline
PureTech Announces Positive Results from Phase 1b Trial of LYT-200 for High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia

PureTech Announces Positive Results from Phase 1b Trial of LYT-200 for High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia

PureTech Announces Positive Results from Phase 1b Trial of LYT-200 for High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia
Trendline Trendline
4Moving Biotech Receives FDA Fast Track Designation for Knee Osteoarthritis Drug

4Moving Biotech Receives FDA Fast Track Designation for Knee Osteoarthritis Drug

4Moving Biotech Receives FDA Fast Track Designation for Knee Osteoarthritis Drug
Trendline Trendline
FDA Approves Merck's IDVYNSO for HIV Treatment, Offering New Therapeutic Option

FDA Approves Merck's IDVYNSO for HIV Treatment, Offering New Therapeutic Option

FDA Approves Merck's IDVYNSO for HIV Treatment, Offering New Therapeutic Option
Trendline Trendline
NEOK Bio Highlights Bispecific Antibody Drug Conjugate Pipeline at AACR 2026

NEOK Bio Highlights Bispecific Antibody Drug Conjugate Pipeline at AACR 2026

NEOK Bio Highlights Bispecific Antibody Drug Conjugate Pipeline at AACR 2026
Trendline Trendline
FDA Grants Fast Track Designation to Debiopharm's Ovarian Cancer Therapy

FDA Grants Fast Track Designation to Debiopharm's Ovarian Cancer Therapy

FDA Grants Fast Track Designation to Debiopharm's Ovarian Cancer Therapy
Trendline Trendline
Inhibrx Announces Webcast for Clinical Update on Ozekibart in Colorectal Cancer

Inhibrx Announces Webcast for Clinical Update on Ozekibart in Colorectal Cancer

Inhibrx Announces Webcast for Clinical Update on Ozekibart in Colorectal Cancer
Trendline Trendline
Lantern Pharma's LP-300 Shows Promising Results in Lung Cancer Trial, Seeks FDA Guidance

Lantern Pharma's LP-300 Shows Promising Results in Lung Cancer Trial, Seeks FDA Guidance

Lantern Pharma's LP-300 Shows Promising Results in Lung Cancer Trial, Seeks FDA Guidance
Trendline Trendline
Debiopharm's Ovarian Cancer Treatment Receives FDA Fast Track Designation

Debiopharm's Ovarian Cancer Treatment Receives FDA Fast Track Designation

Debiopharm's Ovarian Cancer Treatment Receives FDA Fast Track Designation
Trendline Trendline
FDA Grants Priority Review for KEYTRUDA and Padcev Combination for Muscle-Invasive Bladder Cancer

FDA Grants Priority Review for KEYTRUDA and Padcev Combination for Muscle-Invasive Bladder Cancer

FDA Grants Priority Review for KEYTRUDA and Padcev Combination for Muscle-Invasive Bladder Cancer
Trendline Trendline
EpiBiologics Begins Phase 1 Study of EPI-326 for EGFR-Driven Cancers

EpiBiologics Begins Phase 1 Study of EPI-326 for EGFR-Driven Cancers

EpiBiologics Begins Phase 1 Study of EPI-326 for EGFR-Driven Cancers